Quick Answer
Protalix BioTherapeutics, Inc. reported Total Revenue of $52.74 million for the year ending 2025.
- Protalix BioTherapeutics, Inc. showed a decrease of -1.2% in Total Revenue from 2024 to 2025.
- This data is from Protalix BioTherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $1.14 million | Q3 2010: $3.18 million | Q1 2011: $4.13 million | Q2 2011: $764.0 thousand | Q3 2011: $1.13 million | Q1 2012: $3.86 million | Q2 2012: $26.11 million | Q3 2012: $3.72 million | Q1 2013: $3.57 million | Q2 2013: $2.26 million | Q3 2013: $2.28 million | Q1 2014: $6.70 million | Q2 2014: $2.43 million | Q3 2014: $2.40 million | Q1 2015: $1.69 million | Q2 2015: $1.34 million | Q3 2015: $1.34 million | Q1 2016: $679.0 thousand | Q2 2016: $1.77 million | Q3 2016: $4.67 million | Q1 2017: $2.89 million | Q2 2017: $6.36 million | Q3 2017: $7.53 million | Q1 2018: $4.55 million | Q2 2018: $2.01 million | Q3 2018: $663.0 thousand | Q1 2019: $10.44 million | Q2 2019: $12.25 million | Q3 2019: $14.25 million | Q1 2020: $21.65 million | Q2 2020: $10.97 million | Q3 2020: $10.79 million | Q1 2021: $11.32 million | Q2 2021: $6.43 million | Q3 2021: $12.05 million | Q1 2022: $16.09 million | Q2 2022: $8.75 million | Q3 2022: $14.18 million | Q1 2023: $9.59 million | Q2 2023: $35.08 million | Q3 2023: $10.35 million | Q1 2024: $3.75 million | Q2 2024: $13.47 million | Q3 2024: $17.96 million | Q1 2025: $10.11 million | Q2 2025: $15.66 million | Q3 2025: $17.85 million.
- Over the full 17 years of available data (2009 to 2025), Protalix BioTherapeutics, Inc.'s Total Revenue has grown by 13,493.8%.
- Historical annual values: Fiscal year 2025: $52.74 million | Fiscal year 2024: $53.40 million | Fiscal year 2023: $65.49 million | Fiscal year 2022: $47.64 million | Fiscal year 2021: $38.35 million | Fiscal year 2020: $62.90 million | Fiscal year 2019: $54.69 million | Fiscal year 2018: $34.24 million | Fiscal year 2017: $21.08 million | Fiscal year 2016: $9.20 million | Fiscal year 2015: $4.36 million | Fiscal year 2014: $3.52 million | Fiscal year 2013: $0.00 | Fiscal year 2012: $34.87 million | Fiscal year 2011: $8.39 million | Fiscal year 2010: $6.64 million | Fiscal year 2009: $388.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: